Schedule 13G ownership disclosure
Stoke Therapeutics Inc
Common Stock · CUSIP: 86150R107
Event date: 2025-06-30
- Filing-level shares
- 2,550,341
- Percent of class
- 4.7%
- BlackRock Portfolio Management LLC
Shares: 2,550,341 · Class: 4.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002052113-25-002218
- Form type
- SCHEDULE 13G/A
- Filer
- BlackRock Portfolio Management LLC
- CIK
- CIK 2052113
- Filed
- Jul 15, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership